Results 141 to 150 of about 28,823 (297)
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To investigate the efficacy and safety of intensifying once‐weekly insulin icodec (icodec) with once‐weekly semaglutide in adults with type 2 diabetes (T2D). Materials and Methods ONWARDS 8 was a single‐arm, open‐label, treat‐to‐target, Phase 3b trial comprising a 26‐week icodec run‐in period and a 26‐week semaglutide intensification ...
Krzysztof Strojek +5 more
wiley +1 more source
Dipeptidyl peptidase-4 inhibitors and osteoporosis
Journal of the Chinese Medical Association, 2022 Lee, Wen-Ling +2 more
openaire +2 more sources
Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. [PDF]
, 2008 Udgivelsesdato: 2008-AprTakeda San Diego Inc is developing alogliptin, a small-molecule, orally available dipeptidyl peptidase IV (DPP IV) inhibitor, for the potential treatment of type 2 diabetes.
Deacon, Carolyn F
core
Exercise or Fasting in Individuals With Type 2 Diabetes Receiving Once‐Weekly Basal Insulin Icodec
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To investigate glucose levels and hypoglycaemia risk during exercise or fasting in adults with type 2 diabetes (T2D) treated with once‐weekly basal insulin icodec. Materials and Methods Thirty basal insulin‐treated, physically active individuals with T2D (18–75 years, glycated haemoglobin ≤ 75 mmol/mol, peak oxygen uptake > 20 mL/kg/min ...
Thomas R. Pieber +10 more
wiley +1 more source
Understanding how enzymes work: the journey to ensemble–function studies
The FEBS Journal, EarlyView.For decades, structure–function has dominated biochemistry. Structures are highly valuable, yet more is needed to achieve a quantitative understanding of biomolecular function, because function emerges from an ensemble of states, rather than a static structure. We describe an ensemble–function framework applied to quantitatively dissect serine protease
Daniel Herschlag, Siyuan Du
wiley +1 more source
Hepatology Research, EarlyView.Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori +17 more
wiley +1 more source
The Role of Neuropeptide Y in Dental Pulp: Balancing Neurogenic Inflammation and Pain Modulation
International Endodontic Journal, EarlyView.ABSTRACT Background Dental pulp is a densely innervated, low‐compliance tissue in which neurogenic inflammation can rapidly escalate into oedema, raised intrapulpal pressure, microvascular compromise, and pain. While Substance P (SP) and Calcitonin gene‐related peptide (CGRP) are well‐established drivers of pulp vasodilation, the Neuroopeptide Y (NPY ...
Javier Caviedes‐Bucheli +3 more
wiley +1 more source
Linagliptin: from bench to bedside
Drug Design, Development and Therapy, 2014 John DoupisIatriko Palaiou Falirou Medical Center, Division of Diabetes, Athens, GreecePurpose: The nature of biomedical research affords a broad range of investigational topics at the preclinical stage, not all of which may be explored in subsequent ...
Doupis J
doaj